BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.

Rhea-AI Summary

BioStem Technologies Inc. (OTCQB: BSEM) announced its acquisition of the majority assets from Auxocell Laboratories, Inc., a leading manufacturer in solid tissue processing equipment. This acquisition includes all assets excluding the AUX003 patent family, which will be licensed to BioStem. The deal encompasses 45 patents and 11 trademarks related to human placental tissue applications. The acquisition aims to enhance BioStem's intellectual property portfolio and manufacturing capabilities while accelerating growth in regenerative medicine. CEO Jason Matuszewski emphasized the strategic value of Auxocell's technology in producing regenerative products without enzymatic digestion.

Positive

• Acquisition of 45 patents and 11 trademarks enhances BioStem’s intellectual property portfolio.
• Strategic acquisition expected to accelerate BioStem’s growth in regenerative medicine.
• Access to Auxocell’s technology allows for improved manufacturing processes.

Negative

• None.

POMPANO BEACH, FLORIDA., March 07, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company”) (OTCQB: BSEM), announced today that it has entered into an Agreement to acquire the majority of the assets of Auxocell Laboratories, Inc. ("Auxocell”), a leading solid tissue processing equipment manufacturer.

Auxocell is the inventor and manufacturer of the Auxocell solid tissue processing device (AC:Px^®), a single-use, sterile processing system. The AC:Px^® can be used to produce a wide range of regenerative medicine products from a variety of solid tissues such as umbilical, placenta, adipose and deceased donor organs where a match is unable to be located for an organ transplant. Auxocell invested significant capital into the development of the robust patented portfolio. The AC:Px^® allows for greater processing output and increased cell yield when producing native cellular products, minced tissue products and life changing decellularized allografts.

Jason Matuszewski, Chief Executive Officer of BioStem commented: “The acquisition will enable us to expand our intellectual property portfolio, both domestic and foreign, in the perinatal tissue space and provide additional value to our clients and shareholders. The core technology will allow us to secure the manufacturing process to isolate cells from solid tissues without the use of enzymatic digestion. The addition of Auxocell’s assets will allow us to leverage their expertise and resources to enhance our manufacturing capabilities and accelerate our growth trajectory in the marketplace”.

“We are pleased to announce this agreement with BioStem,” said Kyle Cetrulo Co-Founder and Chief Executive Officer of Auxocell Laboratories, Inc. “BioStem has been a customer of Auxocell’s for many years and we are excited to pass this industry leading technology to them. I look forward to seeing how BioStem utilizes the AC:Px^® technology to create life changing regenerative medicine products that advance the field of cellular and tissue therapy.”

Under the terms of the agreement, BioStem will purchase all of Auxocell’s rights, title and interest to all assets with the exception of the AUX003 patent family, which will be licensed to BioStem by Auxocell. In total, Biostem will obtain 45 domestic and foreign issued patents, 11 domestic and foreign trademarks, and all remaining Auxocell equipment and inventory. The Auxocell patent portfolio, trademarks, devices and inventory are all related to the formulation, composition and manufacturing of products derived from human placental tissues and cells.

“By combining our strengths and knowledge with Auxocell’s technology, we will generate innovative solutions to drive long-term success for our business”, said Jason Matuszewski, Chief Executive Officer of BioStem.

About BioStem Technologies, Inc. (OTCQB: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain^® processing method. BioRetain^® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE^TM, VENDAJE^TM AC, and VENDAJE^TM OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. 

Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies

Media and Investor Relations:
Russo Partners, LLC
Nic Johnson
12 West 27th Street, 4th Floor
New York, NY 10001
T: 303-482-6405
Nic.Johnson@russopartnersllc.com

FAQ

What are the key details of the BioStem Technologies acquisition of Auxocell Laboratories?

BioStem Technologies is acquiring the majority of Auxocell's assets, including 45 patents and 11 trademarks, excluding the AUX003 patent family which will be licensed to BioStem.

How will the acquisition of Auxocell affect BioStem Technologies' market position?

The acquisition is expected to strengthen BioStem's intellectual property and enhance its manufacturing capabilities in the regenerative medicine market.

What is the technology involved in BioStem's acquisition of Auxocell?

The acquisition includes Auxocell’s AC:Px® technology, a single-use system for solid tissue processing, allowing for higher output and cell yield.

When was the acquisition of Auxocell Laboratories announced?

The acquisition was announced on March 7, 2023.